2000px-Seal_of_the_United_States_Senate.svg

S.1801 Proposes “Innovation Incentive Fund for New and More Effective Treatments for Bacterial Infections.” Proposal delinks incentives from prices.

On June 12, 2019, 15 members of the U.S. Senate introduced S.1801 (116th Congress), a bill to make medicines more affordable. Among the provisions of the bill, which also include a study of delinkage of R&D financing from pricing, is a Innovation Incentive Fund for New and More Effective Treatments for Bacterial Infections. Section 301 Read more about S.1801 Proposes “Innovation Incentive Fund for New and More Effective Treatments for Bacterial Infections.” Proposal delinks incentives from prices.[…]

Senator Tina Smith

S. 1801: Affordable Medications Act (116th Congress), calls for study of delinkage

On June 12, 2019, 15 US Senators introduced S.1801, a bill to make medicines more affordable. Among the provisions in the bill are a study of the feasibility of progressively delinking R&D costs from product prices. S. 1801: Affordable Medications Act Ms. Smith (for herself, Ms. Klobuchar, Mr. Blumenthal, Mr. Udall, Mr. Brown, Ms. Warren, Read more about S. 1801: Affordable Medications Act (116th Congress), calls for study of delinkage[…]

EllentHoen

Growing consensus on importance of delinkage in pharmaceutical R&D

By Ellen ‘t Hoen The movement to delink the cost of developing medicines from their market price received another boost this week, with the publication of a new report from the Netherlands Council for Public Health and Society, an official government advisory body. This report is part of a recent phenomenon in which even the Read more about Growing consensus on importance of delinkage in pharmaceutical R&D[…]

paccarb_logo

Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria unanimously endorses delinkage

On Thursday, September 14, 2017, the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria unanimously endorsed a report that included very powerful recommendations on delinkage. This is a link to the report that was approved. One of the key recommendations follows: Adoption of some form of a delinkage model as a pull incentive. Delinkage is a Read more about Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria unanimously endorses delinkage[…]

Al Franken Official Senate Portrait

Franken and Schakowsky Drug Pricing Bill Contains Prize Fund for Antibiotics, Delinkage Study

Senator Al Franken, D-Minn., and Representative Jan Schakowsky, D-Ill., along with various high-ranking Democrats in the House and Senate, introduced the Improving Access To Affordable Prescription Drugs Act (S. 771 and H.R. 1776) on March 29, 2017. The bill contains a provision that would create a prize fund for antibiotics. The prize fund would initially Read more about Franken and Schakowsky Drug Pricing Bill Contains Prize Fund for Antibiotics, Delinkage Study[…]

Sanders-021507-18335- 0004

Sen. Sanders Introduces Medical Innovation Prize Fund Act

On March 2, 2017, Senator Bernie Sanders, I-Vt., introduced the Medical Innovation Prize Fund Act (S. 495), which would create an over $100 billion prize fund (set at 0.55-percent of the United States GDP) to reward medical innovation in lieu of the grant of monopolies on new drugs. This bill, which is substantively similar to various Read more about Sen. Sanders Introduces Medical Innovation Prize Fund Act[…]

WHO Logo

India, With Brazil, Proposes Delinkage Feasibility Study in WHA Cancer Resolution

During negotiations on the cancer resolution at the World Health Organization Executive Board meeting in January 2017, India, with the support of Brazil, proposed adding language to a resolution on cancer that would require the WHO to conduct a feasibility study on the creation of a multi-country push and pull fund for cancer research and Read more about India, With Brazil, Proposes Delinkage Feasibility Study in WHA Cancer Resolution[…]

Dirksen Senate Office Building

December 2016 Meeting on Delinkage in U.S. Senate

On December 2, 2016, Knowledge Ecology International hosted a technical meeting on delinkage at the United States Senate. The meeting included panels on various aspects of delinkage, including end product prizes, open source dividends, and antibiotics. Slide presentations from the meeting are available on the KEI website. A recording of the event is on YouTube.

Headshot of Dr. Peter Bach

Dr. Peter Bach Endorses Delinkage for Orphan Drugs

At an October 21, 2016 Partnership for Quality Care drug pricing forum at the Kaiser Permanent Center for Total Health in Washington, D.C., Dr. Peter Bach, the Director of the Center for Health Policy and Outcomes at Memorial Sloan-Kettering Cancer Center, endorsed the idea of delinkage in connection with his proposals on value-based pricing. In particular, Read more about Dr. Peter Bach Endorses Delinkage for Orphan Drugs[…]

un

UN Backs Delinkage in Political Declaration of the High-Level Meeting of the General Assembly on Antimicrobial Resistance

A September 21, 2016 high level meeting of the United Nations General Assembly on antimicrobial resistance endorsed delinking the cost of R&D from the price and volume of sales. The documents from the meeting are available here: http://www.un.org/pga/71/event-latest/high-level-meeting-on-antimicrobial-resistance/. The relevant part of the political declaration was as follows: (c) Underline also that all research and Read more about UN Backs Delinkage in Political Declaration of the High-Level Meeting of the General Assembly on Antimicrobial Resistance[…]